Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population

BACKGROUND: Canagliflozin is the first sodium-glucose co-transporter-2 (SGLT-2) inhibitor—a new class of oral antidiabetic (OAD) medication— approved for type 2 diabetes mellitus (T2DM) treatment in the United States. Approved less than 2 years ago, use of canagliflozin is largely uncharacterized. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Michael, Grabner, Xiaomei, Peng, Geremakis, Caroline, Bae, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398281/
https://www.ncbi.nlm.nih.gov/pubmed/26679969
http://dx.doi.org/10.18553/jmcp.2015.21.12.1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398281/
https://www.ncbi.nlm.nih.gov/pubmed/26679969
http://dx.doi.org/10.18553/jmcp.2015.21.12.1204

Ejemplares similares